Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 349 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Attention Control Clear all
Suspended Phase 3 Interventional

Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301

NCT05924594
View directory record Official record
Conditions
ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity
Interventions
CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg, CTx-1301 - Dexmethylphenidate 25.0mg, CTx-1301 - Dexmethylphenidate 31.25mg, CTx-1301 - Dexmethylphenidate 37.5mg, Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Maitland, Florida • Las Vegas, Nevada • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

NCT00922636
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
LY2216684, Methylphenidate, Placebo (tablet), Placebo (capsule)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Spring Valley, California • Bradenton, Florida • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

NCT00300274
View directory record Official record
Conditions
Graft Rejection
Interventions
everolimus, mycophenolate mofetil, cyclosporine, corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Phase 2 Interventional Results available

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

NCT03310580
View directory record Official record
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Placebo
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
40
States / cities
Chandler, Arizona • Phoenix, Arizona • Azusa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Phase 2 Interventional Results available

A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence

NCT00421603
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Adderall-XR and Topiramate, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 21, 2026, 11:59 PM EDT
Completed No phase listed Observational

Behavior in Children With Attention Deficit Hyperactivity Disorder and in Healthy Volunteers

NCT00026546
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 17 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

NCT00531752
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
PF-03654746, Placebo capsules
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Lafayette, California • Los Alamitos, California • Newport Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 21, 2026, 11:59 PM EDT
Recruiting Not applicable Interventional

Expectant Moms Managing Attention-Deficit/ Hyperactivity Disorder

NCT07001293
View directory record Official record
Conditions
ADHD, Perinatal, Behavioral Intervention
Interventions
MomMA Intervention, Treatment as Usual (TAU)
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 21, 2026, 11:59 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

NCT01345864
View directory record Official record
Conditions
Healthy
Interventions
Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD

NCT01711021
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
d-Amphetamine Transdermal Patch, Placebo patch
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Irvine, California • Miami, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Phase 2 Interventional Results available

Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa

NCT00983814
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Droxidopa+Carbidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 21, 2026, 11:59 PM EDT
Recruiting Not applicable Interventional

Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) Multi-Site RCT

NCT05442957
View directory record Official record
Conditions
Head and Neck Cancer, Body Image Disturbance, Body Image, Survivorship, Psychosocial Impairment, Mental Health Issue
Interventions
BRIGHT, Attention Control
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Detroit, Michigan • St Louis, Missouri • Hershey, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Not applicable Interventional Results available

Brief Behavioral Treatment for Insomnia in Cancer Survivors

NCT03810365
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Brief behavioral treatment for insomnia, Healthy Eating Control
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT02547428
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
CTN SR, Matching placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Phase 4 Interventional Results available

A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD

NCT02683265
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Aptensio XR, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 6 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Las Vegas, Nevada • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Not applicable Interventional Results available

Programs To Support You During Chemotherapy

NCT02489422
View directory record Official record
Conditions
Depression, Fatigue, Stage IIA Colorectal Cancer, Stage IIB Colorectal Cancer, Stage IIC Colorectal Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IIIC Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Appendix Cancer, Stomach Cancer, Gallbladder Cancer, Liver Cancer, Small Intestine Cancer, Large Intestine Cancer, Anal Cancer, Biliary Tract Cancer, Gastrointestinal Stromal Cancer
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration, Daily Survey Administration, Yoga Skills Training, Attention Control, Actigraphy Assessment
Other · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Not applicable Interventional

Community Based Intervention for Children With ADHD and ASD

NCT03003286
View directory record Official record
Conditions
Autism Spectrum Disorder, Attention Deficit-Hyperactivity Disorder, Executive Function
Interventions
Unstuck and on Target (UOT), Parents and Teachers Supporting Students (PATSS)
Behavioral
Lead sponsor
Lauren Kenworthy
Other
Eligibility
8 Years to 11 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 21, 2026, 11:59 PM EDT
Not listed Not applicable Interventional

Fall Risk Reduction in Multiple Sclerosis (FIRMS)

NCT02314585
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Exercise, Education
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Phase 4 Interventional

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

NCT00228046
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
Interventions
Divalproex Sodium, Methylphenidate, Dextroamphetamine, Mixed Amphetamine Salts, Family Counseling, Behavior Management Training with Parents
Drug · Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 14 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Hyde Park, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

NCT02139124
View directory record Official record
Conditions
ADHD
Interventions
Placebo, PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg, PRC-063 100 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
33
States / cities
Los Angeles, California • National City, California • Newport Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genetic Basis for Variation in the Renal Elimination of Metformin

NCT00187720
View directory record Official record
Conditions
Other Conditions That May Be A Focus of Clinical Attention
Interventions
Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 21, 2026, 11:59 PM EDT
Not listed Early Phase 1 Interventional

Photobiomodulation to Improve Cognition in TBI, With fMRI

NCT04230577
View directory record Official record
Conditions
Traumatic Brain Injury, Closed Head Injury, Cognitive Dysfunction
Interventions
Real LED Intervention, Sham LED Intervention
Device
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 21, 2026, 11:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05

NCT05387083
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Low Dose TP-05, High Dose TP-05, Placebo Comparator
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 11:59 PM EDT
Recruiting Not applicable Interventional

Pediatric Epilepsy

NCT07350551
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Cedrus RB series response pad; Adtech Behnke-Fried micro-electrodes; Neuralynx or Blackrock electrophysiology system; Blackrock Cerestim or Natus Nicolet stimulator
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 25 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 11:59 PM EDT